COLO B Coloplast A/S Class B

Coloplast appoints new President of its global Interventional Urology business

Coloplast appoints new President of its global Interventional Urology business

Effective January 2, 2023, Tommy Johns will enter a new role as President & Senior Vice President of Coloplast’s global Interventional Urology (IU) business, replacing Steve Blum, who has decided to retire at the end of 2022.

"Tommy has been with the company since 2015 and is the right person to lead our IU business going forward. He currently leads the IU Global Marketing & Innovation function, and as part of the global leadership team, he has helped bring the organization to where it is today. Tommy is a great ambassador for Coloplast and our company values and through his collaborative spirit he has built strong relationships not just in IU but across the Coloplast Group.” says Kristian Villumsen, Coloplast’s CEO.

Tommy Johns brings 30 years of experience in the medical device industry through his careers with Medtronic, Smiths Medical and Coloplast. He began his career with Coloplast in 2015 as Vice President and General Manager, Urology Care, North America, and was promoted the following year to Vice President of Global Marketing and Innovation, Interventional Urology.

"I am passionate about the work we do in Interventional Urology and I am excited to step into a new role. I look forward to leading our IU business into the future where we will bring existing and new products and solutions to more and more customers around the world. We are a purpose-driven growth business – and a great place to work," says Tommy Johns.

Tommy Johns replaces Steve Blum who has decided to retire after several successful decades in the global healthcare industry, including six years with Coloplast.

“Steve is a great leader with an impressive track record. He has successfully led the IU team through the pandemic, while simultaneously preparing the business for growth. Currently, we are seeing solid growth rates across IU and combined with the investments we have been making into innovation, the business is in a very good place. I want to thank Steve for his contributions to the company and wish him a happy retirement,” says Kristian Villumsen.

About Coloplast 

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care, Interventional Urology and Voice & Respiratory Care. We operate globally and employ more than 14,000 employees.

Global Press Contact 

Peter Mønster, Senior Media Relations Manager 

 

 

   

U.S. Press Contact 

Kate Merwin, Head of Communications 

612-286-2455 

 



Attachments



EN
15/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Coloplast AS: 1 director

A director at Coloplast AS bought 2,150 shares at 463.200DKK and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

 PRESS RELEASE

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående p...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier Se venligst vedlagte pdf.   Vedhæftet fil

 PRESS RELEASE

Coloplast A/S - Trading in Coloplast shares by board members, executiv...

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Please see enclosed pdf.   Attachment

 PRESS RELEASE

Coloplast udnævner Gavin Wood som ny CEO

Coloplast udnævner Gavin Wood som ny CEO Selskabsmeddelelse nr. 3/2026 Intern viden Coloplast udnævner Gavin Wood som ny CEO Det er med glæde, at Coloplasts bestyrelse kan annoncere udnævnelsen af Gavin Wood som ny CEO fra den 1. maj 2026. Gavin Wood afløser Lars Rasmussen, der har været midlertidig CEO siden den 5. maj 2025. Gavin Wood har i to årtier bestredet forskellige ledelsesroller i Johnson & Johnson, senest som øverste leder for Johnson & Johnson MedTech EMEA, en forretning der omsætter for adskillige milliarder dollars og har mere end 7000 medarbejdere på tværs af tre forretnin...

 PRESS RELEASE

Coloplast appoints Gavin Wood as new CEO

Coloplast appoints Gavin Wood as new CEO Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is pleased to announce the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-do...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch